Cannabidiol (CBD): A New Frontier
While CBD is a component of cannabis/marijuana (one of hundreds), it does not cause a high. As the World Health Organisation says:
“In humans, CBD exhibits no effects indicative of any abuse or dependence potential. To date, there is no evidence of public health-related problems associated with the use of pure CBD.”
Cannabidiol (CBD): A New Frontier
While CBD is a component of cannabis/marijuana (one of hundreds), it does not cause a high. As the World Health Organisation says:
“In humans, CBD exhibits no effects indicative of any abuse or dependence potential. To date, there is no evidence of public health-related problems associated with the use of pure CBD.”
With its potential to improve mood, it is applied in the treatment of conditions such as depression and anxiety. It has also become a popular method of pain management. Although there is currently no concrete scientific evidence to support its wide application, many people have embraced it.
According to a report by Grand View Research Inc, the global legal marijuana market size is expected to reach $66.3 billion by the end of 2025.
SLSG’s mission is to become the number one globally trusted supplier of organic, farm-fresh CBD products. We will have production, manufacturing and certification across all continents, supplying global healtcare and wellness cannabis operators with locally grown and manufactured pharmaceutical-grade products. Trust is our priority.
SLSG Technology will lead the way with our proprietary blockchain, which will manage the entire supply chain, from seed to end consumer. Our solution will give us a significant advantage over multiple players in the CBD market today, who simply won’t meet the future EU ‘Novel Foods’ requirements, which we anticipate will be followed by similar regulations from the FDA in the USA and equivalent organisations in other countries.
CBD is used for a wide variety of health issues.
Still, the strongest scientific evidence is for its effectiveness in treating some of the cruellest forms of childhood epilepsy, such as Dravet Syndrome and Lennox-Gastaut Syndrome (LGS), which typically do not respond to anti-seizure products. In numerous studies, CBD reduced the number of seizures – and in some cases was able to stop them altogether. Videos of the effects of CBD on these children and their seizures are readily available online, and they’re very striking. Recently, the FDA approved the first-ever cannabis-derived products for these conditions – Epidiolex, which contains CBD.
CBD is also commonly used to address anxiety, while studies suggest that it may help patients who suffer the misery of insomnia to fall asleep and stay asleep.
Using cannabis in healthcare means our cultivation must abide by strict quality standards. At SLSG, we ensure that our entire practice is compliant with GACP standards.
These outline minimum requirements for growers like us to create high-quality, consistent products that will later pass authorisation by agencies that are in charge of licensing the manufacture and sale of pharmaceutical products. GACP also provides guidelines for cultivation practices more specifically, which allows the end-user of the CBD product to be certain that it was produced in a sterile, safe environment. The product is always the same, regardless of the production batch, and it is safe for consumption.
